- Home
- SEED vs CMMB Comparison
SEED vs CMMB Comparison
Compare SEED & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | CMMB |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 13.0M |
| IPO Year | 2005 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SEED | CMMB |
|---|---|---|
| Price | $1.03 | $1.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 26.3K | ★ 37.7K |
| Earning Date | 01-30-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $44.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $0.87 |
| 52 Week High | $2.49 | $3.86 |
Technical Indicators
Market Signals| Indicator | SEED | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 45.22 |
| Support Level | $0.91 | $1.48 |
| Resistance Level | $1.47 | $1.89 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 39.28 | 2.09 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.